Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toyoshi Yanagihara

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Biochemical and Biophysical Research Communications|May 27, 2017
Thymic epithelial cell-specific deletion of Jmjd6 reduces Aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetesToyoshi Yanagihara, Takahiro Tomino, Takehito Uruno, et al.
Expert Opinion on Investigational Drugs|December 5, 2018
Therapeutic targets and early stage clinical trials for pulmonary fibrosisSeidai Sato, Toyoshi Yanagihara, Martin R J Kolb
Cureus|March 19, 2026
Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe AsthmaMakoto Fujimoto, Toyoshi Yanagihara, Yuka Sakaki, et al.
The European Respiratory Journal|June 8, 2023
Endothelial cells in pulmonary fibrosis: more than a bystanderToyoshi Yanagihara, Christophe Guignabert, Martin R J Kolb
Internal Medicine (Tokyo, Japan)|February 22, 2021
Tracheobronchial Chondritis Associated with Immune Checkpoint BlockadeTatsuma Asoh, Toyoshi Yanagihara, Risa Tanaka, et al.
Biochemical and Biophysical Research Communications|August 11, 2017
Corrigendum to "Thymic epithelial cell-specific deletion of Jmjd6 reduces aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetes" [Biochemical and Biophysical Research Communications 489/1 (2017) 8-13]Toyoshi Yanagihara, Takahiro Tomino, Takehito Uruno, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 13, 2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis?Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta, et al.
Expert Opinion on Therapeutic Targets|November 17, 2021
Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implicationsToyoshi Yanagihara, Ciaran Scallan, Kjetil Ask, et al.
Cureus|January 3, 2022
A Case of Drug-Induced Interstitial Lung Disease Caused by Epirubicin and Cyclophosphamide Therapy Before Breast Cancer SurgeryAyaka Egashira, Toyoshi Yanagihara, Naruhiko Ogo, et al.
Cureus|January 27, 2025
Tracheal Pleomorphic Adenoma With Severe Airway ObstructionNatsumi Kushima, Daisuke Himeji, Toyoshi Yanagihara, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Biochemical and Biophysical Research Communications|May 27, 2017
Thymic epithelial cell-specific deletion of Jmjd6 reduces Aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetesToyoshi Yanagihara, Takahiro Tomino, Takehito Uruno, et al.
Expert Opinion on Investigational Drugs|December 5, 2018
Therapeutic targets and early stage clinical trials for pulmonary fibrosisSeidai Sato, Toyoshi Yanagihara, Martin R J Kolb
Cureus|March 19, 2026
Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe AsthmaMakoto Fujimoto, Toyoshi Yanagihara, Yuka Sakaki, et al.
The European Respiratory Journal|June 8, 2023
Endothelial cells in pulmonary fibrosis: more than a bystanderToyoshi Yanagihara, Christophe Guignabert, Martin R J Kolb
Internal Medicine (Tokyo, Japan)|February 22, 2021
Tracheobronchial Chondritis Associated with Immune Checkpoint BlockadeTatsuma Asoh, Toyoshi Yanagihara, Risa Tanaka, et al.
Biochemical and Biophysical Research Communications|August 11, 2017
Corrigendum to "Thymic epithelial cell-specific deletion of Jmjd6 reduces aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetes" [Biochemical and Biophysical Research Communications 489/1 (2017) 8-13]Toyoshi Yanagihara, Takahiro Tomino, Takehito Uruno, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 13, 2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis?Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta, et al.
Expert Opinion on Therapeutic Targets|November 17, 2021
Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implicationsToyoshi Yanagihara, Ciaran Scallan, Kjetil Ask, et al.
Cureus|January 3, 2022
A Case of Drug-Induced Interstitial Lung Disease Caused by Epirubicin and Cyclophosphamide Therapy Before Breast Cancer SurgeryAyaka Egashira, Toyoshi Yanagihara, Naruhiko Ogo, et al.
Cureus|January 27, 2025
Tracheal Pleomorphic Adenoma With Severe Airway ObstructionNatsumi Kushima, Daisuke Himeji, Toyoshi Yanagihara, et al.
Pageof 11